These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
340 related articles for article (PubMed ID: 31674023)
1. PEG-PLA nanoparticles decorated with small-molecule PSMA ligand for targeted delivery of galbanic acid and docetaxel to prostate cancer cells. Afsharzadeh M; Hashemi M; Babaei M; Abnous K; Ramezani M J Cell Physiol; 2020 May; 235(5):4618-4630. PubMed ID: 31674023 [TBL] [Abstract][Full Text] [Related]
2. Glutamate-urea-based PSMA-targeted PLGA nanoparticles for prostate cancer delivery of docetaxel. Saniee F; Shabani Ravari N; Goodarzi N; Amini M; Atyabi F; Saeedian Moghadam E; Dinarvand R Pharm Dev Technol; 2021 Apr; 26(4):381-389. PubMed ID: 33538232 [TBL] [Abstract][Full Text] [Related]
3. A Novel Prostate-Specific Membrane-Antigen (PSMA) Targeted Micelle-Encapsulating Wogonin Inhibits Prostate Cancer Cell Proliferation via Inducing Intrinsic Apoptotic Pathway. Zhang H; Liu X; Wu F; Qin F; Feng P; Xu T; Li X; Yang L Int J Mol Sci; 2016 May; 17(5):. PubMed ID: 27196894 [TBL] [Abstract][Full Text] [Related]
4. Efficacious delivery of protein drugs to prostate cancer cells by PSMA-targeted pH-responsive chimaeric polymersomes. Li X; Yang W; Zou Y; Meng F; Deng C; Zhong Z J Control Release; 2015 Dec; 220(Pt B):704-14. PubMed ID: 26348387 [TBL] [Abstract][Full Text] [Related]
5. Formulation and evaluation of anticancer and antiangiogenesis efficiency of PLA-PEG nanoparticles loaded with galbanic acid in C26 colon carcinoma, in vitro and in vivo. Afsharzadeh M; Abnous K; Yazdian-Robati R; Ataranzadeh A; Ramezani M; Hashemi M J Cell Physiol; 2019 May; 234(5):6099-6107. PubMed ID: 30378118 [TBL] [Abstract][Full Text] [Related]
6. Plumbagin-loaded aptamer-targeted poly D,L-lactic-co-glycolic acid-b-polyethylene glycol nanoparticles for prostate cancer therapy. Pan M; Li W; Yang J; Li Z; Zhao J; Xiao Y; Xing Y; Zhang X; Ju W Medicine (Baltimore); 2017 Jul; 96(30):e7405. PubMed ID: 28746182 [TBL] [Abstract][Full Text] [Related]
8. PSMA-targeted combination brusatol and docetaxel nanotherapeutics for the treatment of prostate cancer. Adekiya TA; Hudson T; Bakare O; Ameyaw EE; Adebayo A; Olajubutu O; Adesina SK Biomed Pharmacother; 2024 Aug; 177():117125. PubMed ID: 39002444 [TBL] [Abstract][Full Text] [Related]
9. Prostate-Specific Membrane Antigen Targeted Deep Tumor Penetration of Polymer Nanocarriers. Meher N; Ashley GW; Bidkar AP; Dhrona S; Fong C; Fontaine SD; Beckford Vera DR; Wilson DM; Seo Y; Santi DV; VanBrocklin HF; Flavell RR ACS Appl Mater Interfaces; 2022 Nov; 14(45):50569-50582. PubMed ID: 36318757 [TBL] [Abstract][Full Text] [Related]
10. Synthesis and Preliminary Biological Assessment of Carborane-Loaded Theranostic Nanoparticles to Target Prostate-Specific Membrane Antigen. Meher N; Seo K; Wang S; Bidkar AP; Fogarty M; Dhrona S; Huang X; Tang R; Blaha C; Evans MJ; Raleigh DR; Jun YW; VanBrocklin HF; Desai TA; Wilson DM; Ozawa T; Flavell RR ACS Appl Mater Interfaces; 2021 Nov; 13(46):54739-54752. PubMed ID: 34752058 [TBL] [Abstract][Full Text] [Related]
11. Au/Doc/Quer@PDA/A10-3.2 Nanoparticles for targeted treatment of docetaxel-resistant prostate cancer. Ye J; Wu Q; Ji Q; You S; Gao S; Zhao G; Xu Q; Liu K; Li P J Biomater Sci Polym Ed; 2024 Aug; 35(11):1631-1655. PubMed ID: 38769597 [TBL] [Abstract][Full Text] [Related]
12. Second-generation aptamer-conjugated PSMA-targeted delivery system for prostate cancer therapy. Wu X; Ding B; Gao J; Wang H; Fan W; Wang X; Zhang W; Wang X; Ye L; Zhang M; Ding X; Liu J; Zhu Q; Gao S Int J Nanomedicine; 2011; 6():1747-56. PubMed ID: 21980237 [TBL] [Abstract][Full Text] [Related]
14. Prostate-specific membrane antigen targeted, glutathione-sensitive nanoparticles loaded with docetaxel and enzalutamide for the delivery to prostate cancer. Chen Y; Xu Z; Lu T; Luo J; Xue H Drug Deliv; 2022 Dec; 29(1):2705-2712. PubMed ID: 35980107 [TBL] [Abstract][Full Text] [Related]
15. A ROS-responsive polymeric prodrug nanosystem with self-amplified drug release for PSMA (-) prostate cancer specific therapy. Wang Y; Zhang Y; Ru Z; Song W; Chen L; Ma H; Sun L J Nanobiotechnology; 2019 Aug; 17(1):91. PubMed ID: 31451114 [TBL] [Abstract][Full Text] [Related]
16. Multifunctional Envelope-Type siRNA Delivery Nanoparticle Platform for Prostate Cancer Therapy. Xu X; Wu J; Liu Y; Saw PE; Tao W; Yu M; Zope H; Si M; Victorious A; Rasmussen J; Ayyash D; Farokhzad OC; Shi J ACS Nano; 2017 Mar; 11(3):2618-2627. PubMed ID: 28240870 [TBL] [Abstract][Full Text] [Related]
17. Prostate-Specific Membrane Antigen Targeted Therapy of Prostate Cancer Using a DUPA-Paclitaxel Conjugate. Lv Q; Yang J; Zhang R; Yang Z; Yang Z; Wang Y; Xu Y; He Z Mol Pharm; 2018 May; 15(5):1842-1852. PubMed ID: 29608845 [TBL] [Abstract][Full Text] [Related]
18. Spacer length impacts the efficacy of targeted docetaxel conjugates in prostate-specific membrane antigen expressing prostate cancer. Peng ZH; Sima M; Salama ME; Kopečková P; Kopeček J J Drug Target; 2013 Dec; 21(10):968-80. PubMed ID: 24160903 [TBL] [Abstract][Full Text] [Related]
19. Synthesis and Cordonnier A; Boyer D; Besse S; Valleix R; Mahiou R; Quintana M; Briat A; Benbakkar M; Penault-Llorca F; Maisonial-Besset A; Maunit B; Tarrit S; Vivier M; Witkowski T; Mazuel L; Degoul F; Miot-Noirault E; Chezal JM J Mater Chem B; 2021 Sep; 9(36):7423-7434. PubMed ID: 34373887 [TBL] [Abstract][Full Text] [Related]
20. Nanoparticle-aptamer bioconjugates: a new approach for targeting prostate cancer cells. Farokhzad OC; Jon S; Khademhosseini A; Tran TN; Lavan DA; Langer R Cancer Res; 2004 Nov; 64(21):7668-72. PubMed ID: 15520166 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]